MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation (NCT07632157) | Clinical Trial Compass
Not Yet RecruitingPhase 3
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation
United States196 participantsStarted 2026-06
Plain-language summary
The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age \> 18 years or older
* Able to provide informed consent
* Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute
* Metoprolol as rate control agent
* English speaking
Exclusion Criteria:
* Hemodynamically unstable patients (SBP \<90, MAP \<65)
* Impaired consciousness
* Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
* Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
* Rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response
* Acute myocardial infarction
* Contraindications to magnesium sulfate (including myasthenia gravis)
* Allergy or sensitivity to any study drugs
* Previously enrolled in this trial during a different patient encounter
* Withdrew from study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is combining magnesium with metoprolol to control heart rate in atrial flutter — is that combination something my doctor thinks could be more effective than using metoprolol alone for my situation?
2Since this trial is Phase 3, what do we already know about the safety of adding intravenous magnesium to metoprolol for rate control, and are there any risks I should be aware of given my current health?
3The trial is listed as 'not yet recruiting' — does my doctor know when it's expected to open, and is it worth waiting for, or should we pursue available rate-control treatments now?
4The main thing this trial is measuring is how well it controls ventricular rate — if my rate comes down but my atrial flutter isn't converted to normal rhythm, what would the next steps be for my overall treatment?
5Are there standard treatments already approved for rapid ventricular response in atrial flutter that my doctor would recommend I consider before or instead of enrolling in this study?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Ventricular rate control
Timeframe: Within the first 2 hours of intravenous magnesium administration